Lee Su-Chan, Nakata Satoshi, Alaali Lujain, Wang Kaixuan, Tsai Pei-Chi, Pham Khoa, Orr Brent A, Tran Quynh T, Asnaghi Laura, Raabe Eric, Eberhart Charles G
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Neurosurgery, Gunma University, Maebashi, Japan.
Neuro Oncol. 2025 Sep 8;27(7):1715-1728. doi: 10.1093/neuonc/noaf096.
BCL-6 corepressor (BCOR) loss-of-function alterations are common in clinically aggressive retinoblastoma. The study aim was to determine if BCOR loss promotes the growth and dissemination of retinoblastoma cells, and identify the pathways it regulates in these retinal tumors of childhood.
Gain- and loss-of-function strategies were used to modulate BCOR levels in a panel of retinoblastoma cell lines, and the effects on proliferation, clonogenicity, apoptosis, and migration were assessed in vitro and in murine xenograft models.
BCOR knockdown or knockout in retinoblastoma lines with high protein levels increased tumor growth, invasion, clonogenicity, and chemoresistance in vitro, while increased expression in low BCOR lines slowed growth. Growth of retinoblastoma xenografts was similarly sensitive to BCOR gain or loss. BCOR reduction resulted in upregulation of IGF1 and activation of IGF1 receptor (IGF1R) signaling, and the effects of IGF1R inhibition were dependent on BCOR level. In vitro, reduction of retinoblastoma growth and induction of apoptosis by the IGF1R inhibitors linsitinib and AEW541 were also significantly stronger in cells with low BCOR as compared to controls. Both linsitinib and AEW541 suppressed colony formation in a dose-dependent manner in BCOR knockout or knockdown cells. Finally, high BCOR levels rendered retinoblastoma xenografts insensitive to linsitinib.
Loss of BCOR function is associated with more aggressive retinoblastoma cell line growth and chemoresistance, at least in part due to increased IGF1R signaling. Inhibiting IGF1R pharmacologically had a marked anti-tumor effect in aggressive retinoblastoma lacking BCOR, suggesting it as a new therapeutic target, although this still needs to be confirmed in clinical samples with BCOR mutations.
BCL-6共抑制因子(BCOR)功能丧失性改变在临床上侵袭性视网膜母细胞瘤中很常见。本研究的目的是确定BCOR缺失是否会促进视网膜母细胞瘤细胞的生长和扩散,并确定其在这些儿童视网膜肿瘤中调节的信号通路。
采用功能获得和功能丧失策略来调节一组视网膜母细胞瘤细胞系中的BCOR水平,并在体外和小鼠异种移植模型中评估其对增殖、克隆形成、凋亡和迁移的影响。
在高蛋白水平的视网膜母细胞瘤细胞系中敲低或敲除BCOR会增加体外肿瘤生长、侵袭、克隆形成和化疗耐药性,而在低BCOR细胞系中增加其表达则会减缓生长。视网膜母细胞瘤异种移植瘤的生长对BCOR的增减同样敏感。BCOR减少导致IGF1上调和IGF1受体(IGF1R)信号激活,IGF1R抑制的效果取决于BCOR水平。在体外,与对照组相比,IGF1R抑制剂林西替尼和AEW541对低BCOR细胞的视网膜母细胞瘤生长抑制和凋亡诱导作用也明显更强。林西替尼和AEW541在BCOR敲除或敲低的细胞中均以剂量依赖性方式抑制集落形成。最后,高BCOR水平使视网膜母细胞瘤异种移植瘤对林西替尼不敏感。
BCOR功能丧失与更具侵袭性的视网膜母细胞瘤细胞系生长和化疗耐药相关,至少部分原因是IGF1R信号增加。在缺乏BCOR的侵袭性视网膜母细胞瘤中,药理抑制IGF1R具有显著的抗肿瘤作用,提示其作为一个新的治疗靶点,尽管这仍需在有BCOR突变的临床样本中得到证实。